Notes
Affiliated with Gilead Sciences.
Reference
Ball G, et al. Cost-Effectiveness of Axicabtagene Ciloleucel (AXI-CEL) and Tisagenlecleucel (TISA-CEL) in Adult Patients with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) in Canada. 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN108, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3339/111288
Rights and permissions
About this article
Cite this article
CAR-T therapy, axicabtagene ciloleucel, cost effective for large B-cell lymphoma in Canada. PharmacoEcon Outcomes News 880, 4 (2021). https://doi.org/10.1007/s40274-021-7762-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7762-4